Table 1.
Characteristics of the 191 participants included in the PREVAC immunological ancillary study (per-protocol population)
| Characteristics | Placebo group, N = 761 | Ad26-MVA group, N = 791 | VSV group, N = 271 | rVSV-booster group, N = 91 |
|---|---|---|---|---|
| Age at enrollment | 24 [21; 30] | 27 [22; 44] | 22 [20; 30] | 26 [19; 29] |
| Age by class | ||||
| 18-29 | 56 (74%) | 43 (54%) | 19 (70%) | 7 (78%) |
| 30-39 | 13 (17%) | 11 (14%) | 5 (19%) | 1 (11%) |
| ≥ 40 | 7 (9.2%) | 25 (32%) | 3 (11%) | 1 (11%) |
| Sex | ||||
| Female | 27 (36%) | 35 (44%) | 15 (56%) | 4 (44%) |
| Male | 49 (64%) | 44 (56%) | 12 (44%) | 5 (56%) |
1median [IQR], n (%).